
Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …

